A 42-year-old man visits a new primary care physician for a general health check-up. He reports feeling well and has no chronic medical conditions. His social history is notable for occasional alcohol consumption and a period of injection drug use during his early twenties. Physical examination shows no abnormalities. The physician initiates universal screening for an infectious disease that the patient is at high risk for. Arrange the following clinical steps in the most appropriate chronological order for the screening, diagnosis, and management of Hepatitis C virus (HCV) infection for this patient.
- 1Perform initial screening with a hepatitis C virus (HCV) antibody enzyme immunoassay
- 2Confirm active infection with a quantitative HCV RNA nucleic acid test
- 3Evaluate the degree of liver scarring using a noninvasive fibrosis staging method (e.g., FIB-4 index or transient elastography)
- 4Prescribe an appropriate direct-acting antiviral (DAA) treatment regimen
- 5Assess for sustained virologic response (SVR) by measuring HCV RNA 12 weeks after completing therapy
Answer
The correct sequence begins with the HCV antibody screening test, followed by quantitative HCV RNA PCR to confirm active infection, noninvasive fibrosis staging to guide management, initiation of DAA therapy, and finally assessing for sustained virologic response (SVR) 12 weeks post-treatment.
The standard clinical cascade for Hepatitis C virus (HCV) begins with an initial screening using an HCV antibody test, which identifies individuals who have ever been exposed to the virus. Because approximately 20% to 30% of acutely infected individuals spontaneously clear the virus, a positive antibody test must be followed by a quantitative HCV RNA PCR test to confirm the presence of active, ongoing infection. Once active viremia is confirmed, it is essential to evaluate the patient for underlying liver damage before starting medication. Noninvasive fibrosis staging methods, such as the FIB-4 index or transient elastography, are used to determine if cirrhosis is present, which critically influences the specific drug regimen, treatment duration, and the need for future hepatocellular carcinoma screening. After the patient's liver status is staged, a regimen of direct-acting antivirals (DAAs) is prescribed. Finally, the efficacy of the treatment is evaluated by checking the HCV RNA level exactly 12 weeks after the completion of the DAA course; an undetectable viral load at this time indicates a sustained virologic response (SVR), equating to a clinical cure.
Step-by-Step Solution
Key Concept
The stepwise diagnostic and therapeutic cascade for Hepatitis C virus (HCV) includes sequential antibody screening, RNA confirmation, fibrosis staging, DAA treatment, and post-treatment SVR evaluation.